E-LIB Suche - Ergebnisse für: Kilickap, S

1

P2.06-10 Disease Progression on PROs in Patients With aNSCL..:

Gümüs, M. ; Kilickap, S. ; Sezer, A....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S321 , 2023

Link: https://doi.org/10.1016/..

2

114M0 First-line cemiplimab for locally advanced non-small ..:

Kalinka, E. ; Bondarenko, I. ; Gogishvili, M....
Journal of Thoracic Oncology. 18 (2023) 4 - p. S106 , 2023

Link: https://doi.org/10.1016/..

3

49P Patient-reported outcomes (PROs) in patients with advan..:

Baramidze, A. ; Gessner, C. ; Gogishvili, M....
Journal of Thoracic Oncology. 18 (2023) 4 - p. S70-S71 , 2023

Link: https://doi.org/10.1016/..

4

230P Clinical outcomes of cyclin-dependent kinase 4-6 (CDK ..:

Yildirim, H.C. ; Mutlu, E. ; Chalabiyev, E....
ESMO Open. 8 (2023) 1 - p. 101418 , 2023

Link: https://doi.org/10.1016/..

5

Metastasis-directed radiotherapy for non-small cell lung ca..:

Kahvecioglu, A. ; Kilickap, S. ; Hurmuz, P.
Cancer/Radiothérapie. 27 (2023) 8 - p. 731-735 , 2023

Link: https://doi.org/10.1016/..

6

75P Patient-reported outcomes (PROs) of cemiplimab + chemot..:

Baramidze, A. ; Gessner, C. ; Gogishvili, M....
Immuno-Oncology and Technology. 20 (2023) - p. 100547 , 2023

Link: https://doi.org/10.1016/..

7

OA09.05 A Phase 3 Study of Serplulimab Plus Chemotherapy as..:

Zhou, C. ; Hu, Y. ; Arkania, E....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S63-S64 , 2023

Link: https://doi.org/10.1016/..

8

P2.06-01 Cemiplimab-Based Treatment in Advanced NSCLC With ..:

Baramidze, A. ; Gessner, C. ; Gogishvili, M....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S316-S317 , 2023

Link: https://doi.org/10.1016/..

9

OA01.05 Three-year Outcomes per PD-L1 Status and Continued ..:

Garassino, M.C. ; Kilickap, S. ; Özgüroğlu, M....
Journal of Thoracic Oncology. 18 (2023) 3 - p. e2-e3 , 2023

Link: https://doi.org/10.1016/..

10

10MO EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first..:

Kilickap, S. ; Özgüroğlu, M. ; Sezer, A....
Journal of Thoracic Oncology. 18 (2023) 4 - p. S42-S43 , 2023

Link: https://doi.org/10.1016/..

11

LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (E..:

Reinmuth, N. ; Özgüroğlu, M. ; Leighl, N.B....
Immuno-Oncology and Technology. 20 (2023) - p. 100692 , 2023

Link: https://doi.org/10.1016/..

12

HPR12 Treatment Inequities Among Cancer Patients Due to Rei..:

Karacin, C ; Hoca, O ; Kilickap, S
Value in Health. 25 (2022) 12 - p. S234 , 2022

Link: https://doi.org/10.1016/..

13

22P Mean platelet volume to lymphocyte ratio: A new biomark..:

Yildirim, H.C. ; Guven, D.C. ; Kus, F....
Immuno-Oncology and Technology. 16 (2022) - p. 100127 , 2022

Link: https://doi.org/10.1016/..

14

Patient-reported outcomes (PROs) of cemiplimab (CEMI) versu..:

Gogishvili, M. ; Kilickap, S. ; Sezer, A....
Journal of Geriatric Oncology. 13 (2022) 8 - p. S3 , 2022

Link: https://doi.org/10.1016/..

15

EP08.01-024 Multicenter Real Life Clinical Outcomes of PDL-..:

Yazici, O. ; Gürler, F. ; Acar, R....
Journal of Thoracic Oncology. 17 (2022) 9 - p. S348 , 2022

Link: https://doi.org/10.1016/..